Brodalumab

Identification

Name
Brodalumab
Accession Number
DB11776
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
AMG 827 / AMG-827 / KHK-4827 / KHK4827
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SiliqSolution210 mgSubcutaneousValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
SiliqInjection210 mg/1SubcutaneousValeant Pharmaceuticals North America2017-02-15Not applicableUs
Categories
UNII
6ZA31Y954Z
CAS number
1174395-19-7

Pharmacology

Indication

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Associated Conditions
Pharmacodynamics

Increase in the level of IL-17 due to blocking of its receptors.

Mechanism of action

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Absorption
Not Available
Volume of distribution

4.62 L.

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance

0.223 L/day.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Brodalumab.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Brodalumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Brodalumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Brodalumab.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Brodalumab.
AbituzumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Brodalumab is combined with Acteoside.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Brodalumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Brodalumab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brodalumab.
Food Interactions
Not Available

References

General References
  1. article [Link]
  2. article [Link]
External Links
KEGG Drug
D10061
PubChem Substance
347911240
Wikipedia
Brodalumab
ATC Codes
L04AC12 — Brodalumab
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePsoriasis1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPsoriasis2
1WithdrawnBasic ScienceAsthma Bronchial1
1, 2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentModerate to Severe Plaque Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentCrohn's Disease (CD)2
2TerminatedTreatmentPsoriasis1
2TerminatedTreatmentPsoriatic Arthritis1
2TerminatedTreatmentRheumatoid Arthritis1
2WithdrawnTreatmentSpondyloarthritis, Axial1
3Active Not RecruitingTreatmentSpondyloarthritis, Axial1
3CompletedTreatmentModerate to Severe Plaque Psoriasis1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis) / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis / Pustular; Psoriasis, Palmaris Et Plantaris1
3CompletedTreatmentPsoriatic Arthritis1
3TerminatedTreatmentModerate to Severe Plaque Psoriasis3
3TerminatedTreatmentPsoriasis1
3TerminatedTreatmentPsoriatic Arthritis1
4Active Not RecruitingTreatmentPsoriasis1
4Not Yet RecruitingTreatmentPsoriasis1
4RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableNot Yet RecruitingNot AvailablePsoriasis1
Not AvailableRecruitingNot AvailableAtopic Dermatitis (AD) / Psoriasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous210 mg/1
SolutionSubcutaneous210 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on November 18, 2018 13:32